Compare CADL & SNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CADL | SNN |
|---|---|---|
| Founded | 1999 | 1856 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Specialties |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 12.3B |
| IPO Year | 2021 | 2002 |
| Metric | CADL | SNN |
|---|---|---|
| Price | $10.84 | $27.60 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 7 | 2 |
| Target Price | $19.00 | ★ $36.25 |
| AVG Volume (30 Days) | 1.1M | ★ 1.7M |
| Earning Date | 05-14-2026 | 03-16-2026 |
| Dividend Yield | N/A | ★ 2.48% |
| EPS Growth | ★ 58.62 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $125,000.00 | N/A |
| Revenue This Year | N/A | $8.58 |
| Revenue Next Year | N/A | $5.60 |
| P/E Ratio | ★ N/A | $64.97 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.35 | $27.23 |
| 52 Week High | $14.00 | $37.51 |
| Indicator | CADL | SNN |
|---|---|---|
| Relative Strength Index (RSI) | 41.77 | 36.68 |
| Support Level | $9.40 | $27.23 |
| Resistance Level | $11.36 | $31.36 |
| Average True Range (ATR) | 0.69 | 0.53 |
| MACD | -0.28 | -0.02 |
| Stochastic Oscillator | 27.99 | 15.65 |
Candel Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The immune cells induced by these viral immunotherapies are believed to target patients' specific tumor antigens, potentially improving responses in immunologically hot tumors while at the same time infiltrating the tumor microenvironment, transforming non-inflamed cold tumors with limited immune response into hot tumors. The company has established two clinical off-the-shelf viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 40% of the UK-based firm's revenue comes from orthopedic products, and another 31% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the US, just over 30% is from other developed markets, and emerging markets account for the remainder.